Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/BridgeBio Pharma eyes growth with Q2 results and FDA review of new drug encaleret

BBIO

$84.48

+$1.68 +2.03%

BridgeBio Pharma eyes growth with Q2 results and FDA review of new drug encaleret

Company Fundamentals

03 Aug 2026

Andrew Wynn

View Source

Bullish

BridgeBio Pharma is set to report its Q2 earnings on August 10, 2026, with analysts expecting $220.91 million in revenue and a loss of $0.63 per share. The FDA recently accepted the New Drug Application for encaleret, targeting a rare genetic condition, with a decision expected by May 2027. This approval could boost future revenues and strengthen BridgeBio's position in rare disease treatments. Despite current losses and high debt, investor optimism remains high due to the promising drug pipeline and stable short-term financials.

More News (BBIO)

BridgeBio to report Q2 2026 financial results and updates on August 10, 2026

BridgeBio Pharma, a biopharmaceutical company specializing in genetic condition treatments, will announce its second quarter 2026 financial results and business updates on August 10, 2026, after market close. The company will hold a conference call a...

Company Fundamentals

Neutral

4 days ago